Our technologies

3D genome data-driven gene editing drug design for higher precision of editing and proprietary lipid nanoparticle to target the kidney to create de-risked in vivo therapeutics.

1.

EPIC-Cure™ Drug Design Platform

3D genome data-driven gene editing drug designer.

Find out more

1.

Targeted Drug Delivery Technology

Proprietary lipid nanoparticle for in vivo kidney delivery.

Find out more

Pipeline

Organ

Clinical Indication

Discovery

Pre-clinical

IND Enabling

Clinical Trials

in Vivo

Stargardt Disease

in vivo

Undisclosed

Pipeline

Clinical Indication

Discovery

IND Enabling

Clinical Trials

Pre-clinical

Autosomal Dominant Polycystic Kidney Disease

(due to mutations in PKD1 gene)

Autosomal Dominant Polycystic Kidney Disease

(due to mutations in PKD2 gene)

Autosomal Recessive Polycystic Kidney Disease

Tubulointerstitial Kidney Disease